



APASL 2020

29TH ANNUAL CONFERENCE

ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

PROGRAM BOOK



WELCOME MESSAGE



Ever since its inception, in August 1978 in Singapore, APASL (Asian Pacific Association for the Study of the Liver) never looks back but stick to its goal towards advancing the science and practice of Hepatology. Today it is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and creates improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region. APASL's main objectives are to promote the latest scientific advancement and education of hepatology science, exchange of information and the development of consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region.

We hold scientific educational symposia/ conferences developed by leading hepatologists periodically. Our events feature expert speakers presenting the finest data in the most happening topics of liver diseases with high-quality scientific-technical presentations, followed by varied supporting program. Each of our events intended to meet the growing demands of hepatology as a core medical specialty and offers participants the right platform to exchange research, discuss outcomes, and interact with colleagues, focused on liver diseases. Our members include all medical professionals dedicated to hepatology — its research, practice, and care. We cover the region from Manchuria in the North, to Australia in the South, to the Pacific Islands in the East and Iran in the West.

Our members are elected on their documented scientific publications. Mentoring, sharing of knowledge and dedication to professional growth and development are among the core values of APASL and its members.

It is a great pleasure for us to invite you to the 29th Annual Conference Asian Pacific for The Study of Liver (APASL) 2020 that will be held 4 - 8th March 2020 in Bali Nusa Dua Convention Center (BNDCC), Bali, Indonesia. The Conference program covering all aspects of hepatology, for that purpose this would be the perfect moment for all of us to join and share the experience, knowledge and also giving the benefits for the population in the Asian Pacific Region.

We are looking forward to welcoming you to Bali.

Sincerely,

Laurentius A. Lesmana
Honorary President

Rino Alvani Gani
President

Irsan Hasan
Vice President





WELCOME MESSAGE



APASL 2020 at Bali is the first major Liver meeting of 2020 in the world. It will bring cutting edge science, evidence based new therapies and guidelines. Join the academic feast and the enjoy beautiful and hospitable Bali.

Shiv K Sarin

ORGANIZING COMMITTEE

International Advisors

Dong Jin Suh Masao Omata
George K Lau Osamu Yokosuka
J H Kao Shiv K Sarin
Ji-Dong Jia Teerha Piratvisuth
Jin L Hou Jose Sollano

National Advisors

Ali Sulaiman Lukman Hakim Zain
Gontar A. Siregar Nurul Akbar
IDN Wibawa Siti Aminah A.
Iswan A. Nusi Unggul Budihusodo
Julius Laurentius A. Lesmana

Honorary President

Laurentius A Lesmana

President

Rino Alvani Gani

Vice President

Irsan Hasan

Secretary General

Andri Sanityoso Sulaiman

Treasurer

Juferdy Kurniawan

Scientific Committee

Chairman

C. Rinaldi Lesmana

Saut Horas Nababan
Chyntia O. M. Jasirwan
Lianda Siregar
Sahat Matondang

Toar JM Lalisang
Hanifah Oswari
Ening Krisnuhoni
Jacub Pandelaki

Errawan Wiradisuria
Imelda M. Loho

Organizing Committee

Bradley J. Waleleng
Bogi Pratomo W.
Kemal Fariz Kalista
Poernomo Boedi
Hery Djagat P.
David H. Muljono

Fardah Akil
Gontar A. Siregar
Begawan Bestari
Arles
Putut Bayupurnama
Ali Imron Yusuf

Fuad Bakry
Indra Marki
Agastjya Wisjnu W.
Fauzi Yusuf

Conference Information

Date : 4 - 8th March 2020 | **Website :** www.apasl2020.org | **Location :** BALI NUSA DUA CONVENTION CENTER (BNDCC) BALI
Kawasan Terpadu ITDC NW/1 Nusa Dua - Bali 80363, Indonesia | **Contact Person :** (Gerry) +62 838 2045 4145



Conference Information



Venue

BALI NUSA DUA CONVENTION CENTER
Kawasan Terpadu ITDC NW/1 Nusa Dua – Bali 80363 Indonesia
T. +62-361-773000; F. +62-361-778880

Host

Asian Pacific Association for the Study of the Liver (APASL)

Organizer

PT. Prohepa

Conference Secretariat

Office 2 Ground Floor BNDCC 1

Official Language

English

Official Website

www.apasl2020.org

Registration

Registration Counter Opening Hours:

4 March 2020, Wednesday	08.00 - 18.30
5 March 2020, Thursday	07.00 - 16.00
6 March 2020, Friday	08.00 - 17.00
7 March 2020, Saturday	08.00 - 17.00

Poster Area

A Scientific poster session will be held during the APASL 2020 to highlight recent development. Please proceed your poster arrangement according to the schedule.

Poster Area will be located at Kintamani Lobby (Mezzanine Floor) and Singaraja Lobby (First Floor)





Conference Information



Wifi

SSID : APASL 2020
Password : APASLbali

Exhibition

There will be an exhibition in conjunction with the Symposium. The exhibition will exhibit the latest technology of pharmacy, diagnostic and therapeutic product in Hepatopancreatobiliary Diseases. The exhibition is located at South Lobby, East Lobby, Jimbaran Lobby 1 & 2 Bali Nusa Dua Convention Center 1

Exhibition Date and Time:

Instalation March, 3th & 4th, 2020
5 March 2020, Thursday
6 March 2020, Friday
7 March 2020, Saturday

08.00 - 17.00
08.00 - 17.00
08.00 - 17.00

Speaker Ready Room

Located at Uluwatu 6 BNDCC 1

Exhibition Date and Time:

Instalation March, 3th & 4th, 2020
5 March 2020, Thursday
6 March 2020, Friday
7 March 2020, Saturday

08.00 - 17.00
08.00 - 17.00
08.00 - 17.00

Abstract

Oral Presentation will be located at Mengwi Room 2, 3 & 5
Poster Area will be located at Kintamani Lobby (Mezzanine Floor) and Singaraja Lobby (First Floor)

Hotel Accomodation

Our Partnership Hotel :
Bali Nusa Dua Beach
Marriot Courtyard
Grand Hyatt Bali
The Westin Resort Nusa Dua Bali
Conrad Bali
Hilton Bali
The Laguna Resort and Spa





Conference Information



Internet Station

BALI NUSA DUA CONVENTION CENTER
Kawasan Terpadu ITDC NW/1 Nusa Dua – Bali 80363 Indonesia
T. +62-361-773000; F. +62-361-778880

Certificate of Attendance

The Committee will send all the certificate to each of emails that already registered in the website system.

Mobile Phone

Please be aware that mobile phones must be switched off during all scientific sessions.

Photography

Taking pictures using flash is forbidden during all scientific sessions.

Lost & Found



Located at Bussiness Centre BNDCC 1

Climate

Indonesia is distinctly tropical. The weather in Bali in September is usually hot and humid with temperatures ranging between 28 – 32 degrees Celsius and the relative humidity is about 88%. There is comparatively little difference between the day time and night time temperatures. All conference sessions will be held in air – conditioned venues.

Electric Current

The electric current in use throughout Indonesia is 220 volt at 50 cycles. In hotels, you may found two sockets for 110 and 220 volt each; or a converter may be obtained through the housekeeping. Power Plug 220 V.





Conference Information



Taxi

Taxis are available at the airport arrival area. Fare around IDR 250,000 or approximately USD 19. Make sure you take a cab from the official stand and NOT from someone offering taxi inside the terminal.

Customs

Maximum items allowed by customs when you visit Indonesia:

- 1 liter of alcoholic beverages
- 200 cigarettes OR 50 cigars OR 100 grams of tobacco
- Perfume the customs probably will not mind you carrying loads of bottles.
- Cameras, video cameras, portable radios, cassette recorders, binoculars and sport equipment are should be taken out during airport departure process. They must be declared to Customs.

You are **prohibited** to carry:

- Firearms
- Narcotics drugs
- Pornography materials
- Chinese printing and medicines
- Transceivers and cordless telephone
- Films, pre-recorded video tapes, laser discs, VCDs, DVDs must be screened by Censor Board.
- Import or export of foreign currencies and travelers' checks are allowed. However, the import and export of Indonesia currency, exceeding 100 million Rupiah is prohibited.

Further information on customs and taxes in Indonesia, log into **www.beacukai.go.id**

IDD

EMERGENCY NUMBER

Police : 110 / +62 - 361 - 110
Fire Department : 113 / +62 - 361 - 113
Ambulance : 118 / +62 - 361 - 118
Sanglah Public Hospital: +62 - 361 - 227 - 911
Search & Rescue : 111, 115 / 151 +62 - 361 - 751 11

DIRECTORY TELEPHONE

NUMBER INFORMATION

Bali : 108 or +62 - 361 - 108
Indonesia : 106 or +62 - 361 - 106

OPERATOR ASSISTED CALLS

Within Indonesia :100
International : 101

COUNTRY CODE : +62

CITY CODE : 361



Conference Information

Nusa Dua Map





ORAL Presentation



Thursday

05.03.2020

Mengwi 2 Room - Session I

- 13.00-15.00 **Chairman : Edward Gane, Australia**
Co-Chair : Abimanyu, Indonesia
- 13.00-13.10 Preoperative Risk Assessment for Delirium After Hepatic Resection in the Elderly: A Prospective Multicenter Study
Atsushi Ishihara
- 13.10-13.20 Relative dose intensity is very important to maximize the effect of lenvatinib among advance hepatocellular carcinoma patients
Takamasa Ohki
- 13.20-13.30 Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, double-blind, randomized, placebo-controlled, phase II study.
Takaomi Kessoku
- 13.30-13.40 Impact of laparoscopic liver resection for hepatocellular carcinoma on the development of postoperative complication
Daisuke Shirai
- 13.40-13.50 Real World Drug Resistance Profile of Hepatitis C Patients Who Failed Direct-Acting Antivirals
Federico Garcia
- 13.50-14.00 Genotype Misclassification and Its Impact on Treatment Choices, Outcomes and Drug Resistance
Federico Garcia
- 14.00-14.10 Characteristic of Resistance-Associated Substitutions in Unusual Hepatitis C Virus (HCV) Subtypes
Federico Garcia

Thursday

05.03.2020

Mengwi 3 Room - Session I

- 13.00-15.00 **Chairman : Aghayeva Gulnara, Azerbaijan**
Co-Chair : Fuad Bakry, Indonesia
- 13.00-13.10 Post-treatments of lenvatinib in patients with advanced hepatocellular carcinoma
Susumu Maruta
- 13.10-13.20 Can near point of care HCV RNA tests serve as holy grail in the HCV care continuum: an evaluation study of Genedrive HCV RNA test
Padhi Abhishek
- 13.20-13.30 Outcomes of non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) at New Zealand Liver transplant Unit (NZLTU) over last 2 decades
Edward Gane
- 13.30-13.40 Dose response with RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Edward Gane
- 13.40-13.50 First clinical experience with RNA interference [RNAi]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)
Edward Gane
- 13.50-14.00 Clinical profile, etiology, outcome and predictors of outcome in upper gastrointestinal bleed patients presenting to medical emergency in a tertiary care centre in India.
Anurag Sachan
- 14.00-14.10 Atezolizumab+bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC): Results from the Global and China enrolment phases of IMbrave150
Sairy Hernandez
- 14.10-14.20 Roles of alcohol consumption in fatty liver in Japanese men and women: A longitudinal study
Moriya Aki





ORAL Presentation



Thursday

05.03.2020

Mengwi 5 Room - Session I

- 13.00-15.00 **Chairman : Anna Lok, USA**
Co-Chair : Ali Imron Yusuf, Indonesia
- 13.00-13.10 Hepatoprotective effect of Tylophora villosa Blume Leaves Extract on Aspartate Aminotransferase and Alanine Aminotransferase Blood Concentrations of Sprague-Dawley Rat Models Induced by Rifampicin and Isoniazid
Sylvia Rianissa Putri
- 13.10-13.20 Pancreatic endosonographic changes in portal cavernoma cholangiopathy and effect of portosystemic shunt surgery in children
Moinak Sen Sarma
- 13.20-13.30 Co-relation of ascitic fluid (AF) appearance, symptoms & severity of cirrhosis in predicting Spontaneous bacterial peritonitis (SBP) in patients of chronic liver disease
Kandpal Ajay
- 13.30-13.40 Comparative study on treatment outcome of Sitagliptin on histological activity and fibrosis score between diabetic and non-diabetic patients with biopsy proven nonalcoholic steatohepatitis
Jhumur Ghosh
- 13.40-13.50 Five Year Experience with 2-Octyl Cyanoacrylate Injection in Gastric Varices in Cardinal Santos Medical Center
Ellaine Wei-Munji
- 13.50-14.00 Tenofovir Alafenamide for chronic hepatitis B patients with Advanced Fibrosis and Partial Virologic Responses to oral nucleos(t)ide analogues" An Interim Report""
Ming-Lung Yu
- 14.00-14.10 Factor associated with treatment failure of DAA for chronic hepatitis C - a nationwide real-world HCV Registry Program (TACR) in Taiwan
Ming-Lung Yu
- 14.10-14.20 Modelling Quality-Adjusted Life Years (QALYs) for Patients with Non-alcoholic Fatty Liver Disease (NAFLD) in Hong Kong
Vincent Wong
- 14.30-14.40 Elevated testosterone increases the risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus
Terry Cheuk-Fung Yip





ORAL Presentation

Session I



Friday

06.03.2020

Mengwi 2 Room - Session I
Young Investigator Awards

10.00-12.00	Chairman : CH Liu, Taiwan Co-Chair : Rushwandi, Indonesia
10.00-10.10	Long term outcomes with carvedilol versus propranolol in patients with index variceal bleed: 6-year follow-up of a randomised controlled trial Srikant Mohta
10.10-10.20	The Incidence of Acute Kidney Injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy using anthracycline in patients with hepatocellular carcinoma Wahyu Purnama
10.20-10.30	Lifestyle Habits and Nonalcoholic Fatty Liver Disease in the Multicenter CAP-Asia Study Dr. Jimmy Lai for Zhang Xinrong
10.30-10.40	A FIB-4-based risk score predicts hepatocellular carcinoma in patients with chronic hepatitis B Terry Cheuk-Fung Yip for Lilian Yan Liang
10.40-10.50	Risk of Spontaneous Bacterial Peritonitis with Use of Proton Pump Inhibitors Among Patients with Liver Cirrhosis"A Systematic Review and Meta-analysis" Marianne Linley Sy
10.50-11.00	Performance evaluation of a point-of-care (POC) molecular test (Xpert® HBV viral load (VL) assay) to strengthen and decentralize Hepatitis B virus management Arvind Khodare
11.00-11.10	Aspirin induces autophagy and alleviates liver fibrosis by modulating liver microbiome and reducing inflammation in mice model of chronic liver injury Adil Bhat
11.10-11.20	Care Cascade Achieved by a Program for Micro-elimination of Perinatal HBV Transmission among Pregnant Women in Peri-urban Yangon, Myanmar Myat Sandi Min
11.20-11.30	Hepatitis B Virus S Gene Mutation Analysis in Occult Hepatitis B Infection in Indigenous People of Keerom, Papua, Indonesia Dhita Prabasari Wibowo
11.30-11.40	Metagenomics Approach Identified Diversity and Composition of Tumor-infiltrating Microbiota in Hepatocellular Carcinoma Yosuke Hirotsu
11.40-11.50	Existence of hepatitis B surface protein mutations and other variants: Demand for hepatitis B infection control in Cambodia Ko Ko
11.50-12.00	Noninvasive indices for monitoring disease course as an Alternative to Vibration Controlled Transient Elastography in Liver Fibrosis Staging in Chronic Hepatitis C: Comparison of Data in Pre and Post-Treatment Period Shubham Jain
12.00-13.00	Lunch - Singaraja Hall





ORAL Presentation

Session I



Friday

06.03.2020

Mengwi 3 Room - Session I

- 10.00-12.00 **Chairman : Ian Homer Y.Cua, Philippines**
Co-Chair : FX. Pridady, Indonesia
- 10.00-10.10 Treatment Efficacy and Safety of Sofosbuvir with Velpatasvir for chronic hepatitis C among uremic patients under maintenance hemodialysis-an interim report of ERASE-C
Ming-Lung Yu
- 10.10-10.20 Fatty liver is common, but did not predict adverse liver and non-liver outcomes in chronic hepatitis B patients
Sui-Weng Wong
- 10.20-10.30 Both hepatitis A and hepatitis D infection may be associated with more advanced liver disease in patients with chronic hepatitis B
Wu Jer-Wei
- 10.30-10.40 Early priming of immune system with toll-like receptor 7 agonist enhanced the therapeutic effect of HBV class A core protein allosteric modulator in preclinical efficacy model
Lu Gao
- 10.40-10.50 Global and regional burden of hepatitis C virus (HCV) mortality and disability-adjust life years (DALYs), 2015-2019: an analysis of the Global Burden of Disease Study 2019
Lindsey Hiebert
- 10.50-11.00 Global and regional burden of hepatitis B virus (HBV) mortality and disability-adjust life years (DALYs), 2015-2019: an analysis of the Global Burden of Disease Study 2019
John W Ward
- 11.00-11.10 NS5B Drug Resistance Mutations in Naive Hepatitis C Virus-Infected Mexican Patients may Reduce Virological-Sustained Response to Direct-Acting Antivirals
Panduro Arturo
- 11.10-11.20 Genetic search started from resected samples of juvenile-onset human cholangiocarcinoma: SKI interacts with microRNA-3648 resulting in cell cycle regulation
Etsushi Kawamura

12.00-13.00

Lunch - Singaraja Hall





ORAL Presentation



Friday

06.03.2020

Mengwi 5 Room - Session I

- 10.00-12.00 **Chairman : Khin Maung Win, Myanmar**
 Co-Chair : Grace Wong, HongKong
- 10.00-10.10 Both alcoholic and non alcoholic steatohepatitis(BASH): A preliminary study from eastern India
Dinesh Meher
- 10.10-10.20 Impact of the liver volume change on shear wave velocity (SWE)
Tsutomu Kanefuji
- 10.20-10.30 A STUDY ON THE ASSOCIATION BETWEEN SEVERITY OF FIBROSIS IN NON ALCOHOLIC FATTY LIVER DISEASE AND VISCERAL FAT VOLUME
Bony George
- 10.30-10.40 The Changes of Degree of Liver Fibrosis in Patients with Hepatitis B infection and Its Correlation to Duration of Therapy
Ni Wayan Wina Dharmesti
- 10.40-10.50 Analgesic efficacy of ultrasound - guided Erector spinae plane block for percutaneous biliary drainage - A randomized control trial
Deepak
- 10.50-11.00 Relationship Of Post-Prandial Lipaemia And Inflammatory Markers In Cases Of Non-Alcoholic Fatty Liver Disease (NAFLD)
Nath Gautam
- 11.00-11.10 Pancreatic endosonographic changes in portal cavernoma cholangiopathy and effect of portosystemic shunt surgery in children
Moinak Sen Sarma
- 11.10-11.20 Second Harmonic Generation (SHG) microscopy and Hepatic venous pressure gradient based validation of a novel histological staging system for alcoholic hepatitis
Patil N
- 11.20-11.30 Proteomic variations presented with chronic dose of alcohol can be captured in low and early exposure
Sudrishti Chaudhary
- 11.30-11.40 Validation of Indian scoring system for diagnosis of Wilson disease in children
Moinak Sen Sarma
- 11.40-11.50 Prevalence of concurrent non-alcoholic fatty liver disease in chronic hepatitis B patients using non-invasive multiparametric MRI
Wai-Kay Seto
- 11.50-12.00 Association Between Non-Alcoholic Fatty Liver Disease and Extrahepatic Malignancy Risk and Mortality: A Systematic Review
Mutiara Lirendra

12.00-13.00

Lunch - Singaraja Hall





ORAL Presentation



Friday

06.03.2020

Mengwi 5 Room - Session II

- 13.00-15.00 **Chairman : Chan Wah Kheong, Malaysia**
Co-Chair : A.M Luthfi Parewangi, Indonesia
- 13.00-13.10 **Anti-HBs level and its correlation with HBV infection profile in Indonesian population**
Korri Elvanita El-Khobar
- 13.10-13.20 **Changes in claudin 2 expression mediates increased gut permeability in patients with acute variceal bleed due to alcohol related cirrhosis**
Kanav Kaushal
- 13.20-13.30 **Comparative Accuracy Of Prognostic Models For Short-Term Mortality Among Acute-On-Chronic-Liver-Failure (ACLF) Patients: An Analysis beyond Receiver Operator Curve (ROC)-CAPS ACLF Study**
Verma Nipun
- 13.30-13.40 **Hepatic Proteomic analysis reveals distinct molecular signatures in double hit model of thioacetamide and ethanol induced liver fibrosis in mice**
Sudrishti Chaudhary

Friday

06.03.2020

Mengwi 3 Room - Session II

- 13.00-15.00 **Chairman : TC Tseng, Taiwan**
Co-Chair : Nasrul Zubir, Indonesia
- 13.00-13.10 **Occult Hepatitis B infection in Hepatitis B-vaccinated elementary school children in Kupang, East Nusa Tenggara**
Muhammad Rezki Rasyak
- 13.10-13.20 **Quality Of Life, Psychosocial Burden And Mental Health Disorders In Primary Caregivers Of Patients With Cirrhosis**
Hareendran Atul
- 13.20-13.30 **Serum cystatin C as a predictor of 90-day mortality in patients admitted with complications of cirrhosis**
Suksamai Anuchit
- 13.30-13.40 **HSD17B13 Insertion Variant Confers Protective Effect on Adverse Liver Outcomes in Patients with Non-alcoholic Fatty Liver Disease**
Ting Yi Wen
- 13.40-13.50 **5-aminolevulinic acid attenuates palmitate-induced endoplasmic reticulum stress and hepatocyte lipooptosis via heme oxygenase-1 induction.**
Takaaki Hashimoto
- 13.50-14.00 **The Role of Non-Neutral Mutation in the NS5A Region of HCV and Virological Response in HCV-HIV Coinfected Patients with Peg-IFN/RBV Therapy**
Juferdy Kurniawan
- 14.00-14.10 **Sarcopenia is a poor prognostic marker following curative resection for hepatocellular carcinoma " a single centre experience**
Edward Gane





ORAL Presentation



Friday

06.03.2020

Mengwi 5 Room - Session II

- 13.00-15.00 **Chairman : Oidov Batarkhuu, Mongolia**
Co-Chair : Fauzy Yusuf, Indonesia
- 13.00-13.10 Glomerular Filtration Rate in Liver Cirrhosis
Niza Amalya
- 13.10-13.20 Expanding the Potential Benefits of Vitamin E in NAFLD Patients: A Meta-Analysis of Randomized Controlled Trials
Adinda Ayu Dyah Rahadini
- 13.20-13.30 Circulating platelets and plasma proteomic profiling during liver regeneration in living liver donors
Adil Bhat
- 13.30-13.40 Stem Cells Therapy as an Initial Treatment Prior to Liver Transplantation for Liver Cirrhosis Case
Samuel Lionardi
- 13.40-13.50 Non alcoholic fatty liver disease in Inflammatory bowel disease -tend to be lean ?
Anju Krishna Krishnakumar
- 13.50-14.00 Piloting practical innovations to increase the efficacy of traditional awareness modalities for general population for spreading awareness about hepatitis B and C infections
Dr. Neeraj Raizada
- 14.00-14.10 Curtailing the silent epidemic of Hepatitis B & C: Experiences in implementation of an innovative Call to action initiative
Dr. Neeraj Raizada
- 14.10-14.20 Study of the effect of the interleukin-18 gene rs1946518 polymorphism on the progression of chronic viral hepatitis B and chronic viral hepatitis B with a delta agent in the Kazakh population
Ilyassova Bibigul
- 14.30-14.40 TREATMENT NONALCOHOLIC STEATOHEPATITIS: OWN EXPERIENCE
Ilyassova Bibigul
- 14.40-14.50 RATIONAL PHARMACOTHERAPY OF PRIMARY BILIARY CHOLANGITIS. OWN EXPERIENCE
Ilyassova Bibigul
- 14.50-15.00 THE EFFECT OF HEPATOCYTE CELL STEM CELL IN VEGF AND CITOLOGY PATIENT OF HEPATOCELLULAR CARCINOMA (HEP G2)
Asih Sasami Jati





ORAL Presentation



Saturday

07.03.2020

Mengwi 2 Room - Session I

- 10.00-12.00 **Chairman : Anna Lok, USA**
Co-Chair : Ming Lung Yu, Taiwan
- 10.00-10.10 CORRELATION BETWEEN TNF- α SERUM AND DEGREE OF LIVER FIBROSIS BY FIBROSCAN IN CHRONIC LIVER DISEASE PATIENTS AT RSMH PALEMBANG
Suyata
- 10.10-10.20 ETHANOL EXTRACT of *Garcinia mangostana* L PERICARP INCREASE BLOOD ALBUMIN CONCENTRATION IN RAT LIVER FIBROSIS MODEL
Triyanta Yuli Pramana
- 10.20-10.30 Cost Analysis of Hospitalized Liver Cirrhosis Patients in Tertiary Referral Hospital
Kemal F. Kalista
- 10.30-10.40 Are patients with non-alcoholic fatty liver disease (NAFLD) at risk of endothelial dysfunction?
Waleed Al-hamoudi
- 10.40-10.50 Prevalence of Biopsy Proven Non Alcoholic Fatty Liver Among Patients with Gallstone disease
Sara Alqahtani
- 10.50-11.00 Noninvasive indices for monitoring disease course as an Alternative to Vibration Controlled Transient Elastography in Liver Fibrosis Staging in Chronic Hepatitis C: Comparison of Data in Pre and Post-Treatment Period
Shubham Jain
- 11.00-11.10 Baseline M2BPGI Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
Tai-Chung Tseng

Saturday

07.03.2020

Mengwi 2 Room - Session I

- 10.00-12.00 **Chairman : Anna Lok, USA**
Co-Chair : Ming Lung Yu, Taiwan
- 10.00-10.10 Perioperative management for portal hypertension in patients with hepatocellular carcinoma
Nobuyuki Takemura
- 10.10-10.20 Feeding Phellodendron bark and its component berberine prevent nonalcoholic steatohepatitis-related fibrosis in mice
Mayuko Ichimura-Shimizu
- 10.20-10.30 Role of the Sabadell NIHCED (non-invasive hepatitis C related cirrhosis early detection) index and right lobe diameter to albumin ratio in prediction of presence of varices in patient with liver cirrhosis
Amr Mohammed Zaghloul
- 10.30-10.40 Same subtype but different strains of hepatitis A virus (HAV) causing outbreaks in two districts of one province in Indonesia almost at the same time
Dewi Setyowati
- 10.40-10.50 Decision curve analysis of non-invasive predictive tools for varices needing treatment in patients with chronic liver disease
Samagra Agarwal
- 10.50-11.00 Impact of transforming growth factor-beta1 gene polymorphism on the development of cirrhosis in chronic hepatitis C patients in Bangladesh.
Jahan Munira
- 11.00-11.10 Study of Prevalence of Hepato-pulmonary Syndrome and its Correlation with CTP/MELD Scores
Dinesh Meher
- 11.10-11.20 Study of Toll-like receptor 3 gene polymorphism as a novel risk factor for HCV-related Hepatocellular Carcinoma in Egypt
Sherief Abd-Elsalam





ORAL Presentation



Saturday

07.03.2020

Mengwi 2 Room - Session II

- 13.00-15.00 **Chairman : TBA**
Co-Chair : Ming Lung Yu, Taiwan
- 13.00-13.10 Longitudinal changes in controlled attenuation parameter and body mass index are associated with fibrosis evolution in chronic hepatitis B patients on nucleoside analogue therapy
Rex Wan-Hin Hui
- 13.10-13.20 Hepatocellular carcinoma post direct-acting antivirals in Australian hepatitis C-related advanced fibrosis/ cirrhosis patients
Emilia Prakoso
- 13.20-13.30 Assessing the role of hepatology nurses in the management of patients with advanced liver disease in the outpatient setting.
Emilia Prakoso
- 13.30-13.40 A new role of cancer stem cell marker CD90/THY-1 in cell autophagy upon chemotherapy
Caecilia Sukowati
- 13.40-13.50 Distribution of cancer stem cells mRNA markers in HCC clinical samples: Eastern vs. Western populations
Caecilia Sukowati
- 13.50-14.00 Fibrosis Index Predicts Subsequent Esophageal variceal Bleeding in Patients with Compensated Cirrhosis and Initial Small Varices without Beta-Blocker or Band Ligation Prophylaxis.
Sheng-Fu Wang
- 14.00-14.10 THE SIDE EFFECTS OF DIRECT ACTING ANTIVIRALS IN HEPATITIS C PATIENTS ARE ASSOCIATED WITH OATP 334 T> G VARIANT
Zuhal MERT ALTINTAS

Saturday

07.03.2020

Mengwi 3 Room - Session II

- 13.00-15.00 **Chairman : TBA**
Co-Chair : TBA
- 13.00-13.10 Early use of oral PEG3350 plus Lactulose vs. Lactulose alone enables early and sustained recovery of overt Hepatic Encephalopathy in patients with Acute on Chronic Liver Failure: An Open Label Randomized Controlled Trial
Madhumita Premkumar
- 13.10-13.20 Comparison of outcomes among decompensated and compensated cirrhosis with autoimmune hepatitis treated with steroids
Samagra Agarwal
- 13.20-13.30 Liver stiffness measurement by Fibroscan increases diagnostic accuracy in non-alcoholic fatty liver disease patients classified as indeterminate risk for advanced fibrosis according noninvasive scores
Yusuf Yilmaz
- 13.30-13.40 Effectiveness of hepatitis C treatment within National Roadmap on prophylaxis, diagnostics, treatment and prevention of consequences of viral hepatitis in the Republic of Kazakhstan
Alexander Nersesov
- 13.40-13.50 Portal vein sclerosis is related to cholangitis episodes and affects survival in Biliary Atresia after Kasai Portoenterostomy.
Khanna Rajeev
- 13.50-14.00 A randomized placebo controlled trial of Tadalafil for erectile dysfunction in patients with cirrhosis
Rakesh Kumar Jagdish
- 14.00-14.10 Comparison of clinical and histological characteristics of biopsy-proven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center
Yusuf Yilmaz
- 14.10-14.20 Efficacy of liver stiffness measurement in the left lobe
Abe Satoshi
- 14.30-14.40 THE EFFECT OF HYPERBARIC OXYGEN THERAPY (HBOT) ON LIVER FUNCTION AND FIBROSIS USING A RAT MODEL OF CARBON TETRACHLORIDE (CCl₄)-INDUCED LIVER INJURY: AN EXPERIMENTAL STUDY
Marc Julius H. Navarro
- 14.40-14.50 NAFLD Disease Burden - Hong Kong, Singapore, South Korea, and Taiwan, 2020-2035
Vincent WS Wong



Scientific Schedule



Wednesday

04.03.2020

08.00 -18.30

Re-registration & On site

Workshop 1 - Nusa Dua Hall 1

Asian EUS Group (AEG) - APASL Endoscopy Course

08.00-08.55 Session I Frontiers Endoscopy in Liver Disease

Chairman : Kazuo Hara, Japan

Co-Chair : Ari Fahrial Syam, Indonesia

08.00-08.15 Endoscopic polypectomy in patients with advanced liver disease

Marcellus Simadibrata, Indonesia

08.15-08.30 ERCP in Advance Liver Cirrhosis

Begawan Bestari, Indonesia

08.30-08.45 ERCP and cholangioscopy in hepatobiliary diseases

Ari Fahrial Syam, Indonesia

08.45-08.55 Discussion

08.55-10.00 Session II EUS Innovation in Hepatobiliary Disorders

Chairan : Kazuo Hara, Japan

Co-Chair : M. Begawan Bestari, Indonesia

08.55-09.00 Welcome Speech & Opening Remarks

Kazuo Hara, Japan

09.00-09.15 Moving towards the diagnostic scene in Liver Biopsy: FNA vs. FNB

Lawrence Ho Khek Yu, Singapore (Webcam)

09.15-09.30 Intraductal Ultrasound in Biliary Malignancy

Murdani Abdullah, Indonesia

09.30-09.45 Impact of EUS in Gallbladder Drainage in Clinical Practice

Mitsuhiro Kida, Japan

09.45-10.00 Current Status EUS-guided Biliary Drainage for Benign and Malignant Biliary Obstruction

Kazuo Hara, Japan

10.00-10.10 Discussion

10.00-10.30

Coffee Break

10.30-12.00 Phantom Hands-on Workshop
All Faculties

10.30-12.00

Phantom Hands-on Workshop RFA
All Faculties

12.00-13.00

Lunch - Singaraja Hall

18.30-20.00

Welcome Dinner - Temple Garden Westin





Scientific Schedule



Wednesday

04.03.2020

08.00 -18.30

Re-registration & On site

Workshop 3 - Nusa Dua Hall 3
APASL-AASLD Clinical Research Workshop

08.00-12.10

Workshop Director :
W Ray Kim, USA
Rino A. Gani, Indonesia

08.00-10.00

Workshop 4 - Uluwatu Hall 1
Challenges in Liver Transplantation and Current
Surgical Innovation in Hepatobiliary Disorders

Chairman : Mureo Kasahara, Japan
Co Chair : Wifanto S. Jeo, Indonesia

08.00-08.05

Introduction
Rino A. Gani, Indonesia

08.00-08.25

Comprehensive Aspects in Living Donor Liver
Transplantation

08.05-08.30

Spectrum of Clinical Research
W. Ray Kim, USA

Toar J.M. Lalisang, Indonesia

08.30-08.55

Setting Up Multicenter Studies
Jasmohan Bajaj, USA

08.25-08.50

Surgical Approach in Large Primary Liver
Tumor

08.55-09.35

Clinical trials: A to Z
Anna Lok, USA
Sample size and data analyses in RCTs

08.50-09.15

Wifanto S. Jeo, Indonesia
Surgery in Metastatic Liver Tumor Non-Col-
orectal Cancer

09.35-10.00

Grace Wong, Hong Kong

09.15-09.40

Adianto Nugroho, Indonesia
Pediatric Liver Transplant: Monosegment
Hepatectomy in Small Baby Recipients

09.40-10.00

Mureo Kasahara, Japan
Discussion

10.00-10.30

Coffee Break

10.30-10.55

Getting Funding for Studies : Industry Sponsored and Investigator-Initiated Trials
Rajender Reddy, USA

10.55-11.20

Preparing Your Abstract
Jasmohan Bajaj, USA

11.20-11.45

Giving an Effective Presentation
W. Ray Kim, USA

11.45-12.10

Getting Your Manuscript Published
Guadalupe Garcia Tsao, USA

12.00-13.00

Lunch - Singaraja Hall

12.40-13.30

POSTER VIEWING
All Faculties

13.30-15.30

Oral Abstract Presentation
Panelist

15.30-15.55

Panel Session: Life as an academic Hepatologist

15.55-16.00

Panelist
Closing/Awarding
W. Ray Kim, USA & Kemal Fariz Kalista, Indonesia

18.30-20.00

Welcome Dinner - Temple Garden Westin





Scientific Schedule



Wednesday

04.03.2020

Post Graduate Course - Nusa Dua Hall 4

Session I - All about Portal Hypertension

- 10.30-12.00 **Chairman : Laurentius A. Lesmana, Indonesia**
Co Chair : Saeed Hamid, Pakistan
- 10.30-10.50 **Hepatic Fibrosis and Development of Portal Hypertension**
Jordy Gracia-Sancho, Spain
- 10.50-11.10 **Non Cirrhotic Portal Hypertension : Pathophysiology and Diagnostic Approach**
Guadalupe Garcia Tsao, USA
- 10.55-11.10 **Management of Non Cirrhotic Portal hypertension and Portal Biliopathy**
Saeed Hamid, Pakistan
- 11.10-11.30 **Non Invasive Assesment of Subclinical and Clinical Portal Hypertension**
Laurent Castera, France
- 11.30-11.50 **Spontaneous Porto-Systemic Shunts, Diagnostic, Clinical, Relevance, and Management**
Hitoshi Maruyama, Japan

12.00-13.00 **Lunch - Singaraja Hall**

Post Graduate Course - Nusa Dua Hall 4

Session II

- 13.00-15.00 **Chairman : Laurent Castera, France**
Co-Chair : C. Rinaldi A. Lesmana, Indonesia
- 13.00-13.20 **Portal Hypertension in Children : Diagnosis and Management**
Rajeev Khanna, India
- 13.20-13.40 **Primary Prophylaxis Variceal Bleeding in Child C Cirrhosis**
Zaigham Abbas, Pakistan
- 13.40-14.00 **Acute Variceal Bleeding Management : Beyond Guideline**
Guadalupe Garcia Tsao, USA
- 14.00-14.20 **Approach to Prevent and Reverse Cirrhotic Cardiomyopathy**
Vincent Ho, Australia
- 14.20-14.40 **Advance Therapeutic Option in Portal Hypertension : Beyond Beta Blocker**
Lianda Siregar, Indonesia
- 14.40-15.00 **Finding the Bridge Between EUS and Liver Disease: Ready for Prime Time?**
C. Rinaldi A. Lesmana, Indonesia

15.00-15.30 **Coffee Break**

Post Graduate Course - Nusa Dua Hall 4

Session III

- 15.30-16.30 **Chairman : Guadalupe Garcia Tsao, USA**
Co-Chair : Hitoshi Maruyama, Japan
- 15.30-15.50 **Cutting-edge of Endoscopic Management in Nonalcoholic Fatty Liver Disease (NAFLD)**
D. Nageshwar Reddy, India
- 15.50-16.10 **Liver Transplantation in Portal Vein Thrombosis : Is Still Contraindication?**
Masatoshi Makuuchi, Japan
- 16.10-16.30 **Wrap up & Closing**
C. Rinaldi A. Lesmana, Indonesia

18.30-20.00 **Welcome Dinner - Temple Garden Westin**





Scientific Schedule



Thursday

05.03.2020

07.00-16.00

Re-registration & On site Including Morning Coffee Break (Jimbaran Lobby)

Symposium 1 - Nusa Dua Hall 1,2,3
Clinical Dilemma in Hepatitis B Virus Infection
and Liver Transplantation

07.30-09.00

Chairman : W. Ray Kim, USA (email)
Co-Chair : Poernomo Boedi Setiawan, Indonesia

07.30-09.00

Symposium 2 - Nusa Dua Hall 4
Autoimmune Liver Diseases: An Update

Chairman : F.X Pridady, Indonesia
Co Chair : Ignatia Sinta Murti, Indonesia

07.30-07.50

Treatment Strategy for HBeAg Positive Normal
ALT Patients With Minimal or No Fibrosis
Poernomo Boedi Setiawan, Indonesia

07.30-07.55

Management of Severe Forms of AIH and With
or Without Cirrhosis

07.50-08.10

Long Term Oral Antiviral Therapy Outcome
in Decompensated Cirrhosis With or Without
CKD

07.55-08.20

C. Rinaldi A. Lesmana, Indonesia
Algorithmic Approach Management of PSC
and It's Complications

08.10-08.30

Anna Lok, USA
Precision Treatment of HBV Infection
IDN Wibawa, Indonesia

08.20-08.45

Ulrich H Beuers, The Netherlands
Managing unresponsive primary biliary
cholangitis

08.30-08.50

Steatosis and Liver Transplantation Outcome:
Current Knowledge and Limitation
Adianto Nugroho, Indonesia

08.45-09.00

Saut Horas Nababan, Indonesia
Discussion

08.45-09.00

Discussion

09.00-09.30

Presidential Lecture - Nusa Dua Hall 5
Chairman : Osamu Yokosuka, Japan & Co-Chair: Lianda Siregar, Indonesia
New Insight of Bacterial Management in Liver Cirrhosis
Laurentius A. Lesmana, Indonesia

09.30-12.15

Opening Ceremony & Award Lecture
(Nusa Dua Hall 5)

12.15-13.00

Lunch - Singaraja Hall

13.00-14.30

Industrial Symposium 1 - Nusa Dua Hall 1,2,3 (EISA)
A New Horizon in The Clinical Management of Unresectable
Hepatocellular Carcinoma

13.00-13.05

Opening and Welcome
Chairman : Irsan Hasan, Indonesia
Co-Chair : Lianda Siregar, Indonesia

13.05-13.25

Update in Clinical Management of Unresectable Hepatocellular Carcinoma: What's New?
Lianda Siregar, Indonesia Addressing the Unmet

13.25-13.50

Medical Needs in Unresectable Hepatocellular Carcinoma - Lenvatinib Data Review
C. Rinaldi A. Lesmana, Indonesia

13.50-14.15

Role of Lenvatinib For Unresectable Hepatocellular Carcinoma: Case Sharing
Rino A. Gani, Indonesia

14.15-14.25

Discussion and Q n A

14.25-14.30

All Participant
Summary and Closing
Irsan Hasan, Indonesia

14.30-15.00

State of The Art Lecture 1 - Nusa Dua Hall 1,2,3
Chairman : Irsan Hasan, Indonesia
Co-Chair : M. Julwan Pribadi, Indonesia
Liver Transplantation for Small HCC: Where Do We Stand?
Toar J. M Lalisang, Indonesia





Scientific Schedule



Thursday

05.03.2020

Special Interest Group 1 - Nusa Dua Hall 4
Palliative Care in Hepato-Pancreato Biliary Disorders

15.00-16.30 **Chairman : Hasmik Ghazinyan, Armenia**
Co-Chair : Arles, Indonesia

15.00-15.25 Palliative and Supportive Care for Patients with End-Stage Liver Disease
Diana A. Payawal, Philippines

15.25-15.50 Palliative Endoscopic Management in Advanced Biliary Cancer
D. Nageshwar Reddy, India

15.50-16.15 Pain Management in Advanced Liver Cancer
Dwi Pantja Wibowo, Indonesia

16.15-16.30 Discussion

Symposium 3 - Nusa Dua Hall 5
Clinical Dilemma and Innovation in HCC Therapy

15.00-16.30 **Chairman : Sahat Matondang, Indonesia**
Co-Chair : Sri Inggriani, Indonesia

15.00-15.20 Microwave Ablation vs RFA
Shuichiro Shiina, Japan
15.20-15.40 TACE in Large HCC :Option Beyond the Limit
Sahat B.R.E Matondang, Indonesia
15.40-16.00 How Can We Realize Anatomical Liver Resection for HCC

Masatoshi Makuuchi, Japan
16.00-16.20 RFA for Metastatic Liver Disease: Impact on Patient's Outcome
Shi-Ming Lin, Taiwan
16.20-16.30 Discussion

16.30-16.50

Coffee Break

Symposium 4 - Nusa Dua Hall 4
Coagulation Disorders and Hypersplenism and in Liver Disease

16.50-18.20 **Chairman : Norifumi Kawada, Japan**
Co-Chair : F. Soemanto Padmomartono, Indonesia

16.50-17.10 Diagnostic approach and stratification management of coagulation disorders in liver cirrhosis
W. Ray Kim, USA

17.10-17.30 Safety issue on long-term oral anti-platelet or anticoagulant therapy in liver cirrhosis patients
Lugyanti Sukrisman, Indonesia

17.30-17.50 Splenectomy in Liver Cirrhosis Patients With Hypersplenism and Splenomegaly
Adianto Nugroho, Indonesia

17.50-18.10 Our 30 years Experience of Living Donor Liver Transplantation
Masatoshi Makuuchi, Japan
18.10-18.20 Discussion

18.30-20.00

Sponsored Dinner Symposium by Minophagen - Dexa Medica

SPONSORED DINNER SYMPOSIUM (Minophagen-Dexa Medica) - Nusa Dua Hall 1,2,3
New Strategies for Management of Chronic Hepatitis

18.30-20.00 **Chairman : Irsan Hasan, Indonesia**

18.30-18.50 Management of Acute on Chronic Liver Failure an Algorithmic Approach
Laurentius A. Lesmana, Indonesia

18.50-19.10 Reversibility of Hepatic Fibrosis in Chronic Hepatitis
Jia-Horng Kao, Taiwan

19.10-19.30 Discussion
19.30-20.00 Dinner



Scientific Schedule



Friday

06.03.2020

08.00-17.00

Re-registration & On site

Symposium 6 - Nusa Dua Hall 1,2,3
Pediatric Hepatology

08.00-09.30 **Chairman : Hanifah Oswari, Indonesia**
Co-Chair : Fatima Safira Alatas, Indonesia

08.00-08.20 Abnormal Liver Enzyme Levels in an Adolescent: What Should You Do?
Ninung Rose, Indonesia

08.20-08.40 Pediatric NAFLD : How to Approach?
Fatima Safira Alatas, Indonesia

08.40-09.00 Referring Patients for Liver Transplantation : Indication, Timing, and The Preparation to Transplantation
Hanifah Oswari, Indonesia

09.00-09.20 Discussion

Symposium 7 - Nusa Dua Hall 4
Perspective on NAFLD in Asia

08.00-09.30 **Chairman : Khin Maung Win, Myanmar**
Co-Chair : Bradley Jimmy Waleleng, Indonesia

08.00-08.20 NAFLD in Asian countries: From Risk Factors, Pathogenesis to Clinical Manifestations
C. Rinaldi A. Lesmana, Indonesia

08.20-08.40 Pathological Point of View in NAFLD with Hepatitis Virus Infection
Marini Stephanie, Indonesia

08.40-09.00 Management Strategy for NAFLD/NASH: Asian's Perspective
Hery Djagat Purnomo, Indonesia

09.00-09.20 Bariatric Surgery in NAFLD: Safety and Efficacy
Errawan Wiradisuria, Indonesia

09.20-09.30 Discussion

Symposium 8 - Nusa Dua Hall 5
Hepatitis Virus Infection and The Others

08.00-09.30 **Chairman : Oidov Batarkhuu, Mongolia**
Co-Chair : Agustinus Taolin, Indonesia

08.00-08.20 HBV - HCV co infection: Viral Load and Outcome after HCV Therapy
Ming Lung Yu, Taiwan

08.20-08.40 Treatment Strategy in Special Population (CKD, HIV, Pregnancy)
CJ Liu, Taiwan

08.40-09.00 The Role of Gut-dysbiosis in Chronic Hepatitis C Virus Infection
Yasuhiro Tanaka, Japan

09.00-09.20 Global Burden of HCV Infection in Eastern Country and its Impact on Treatment Policy
David H. Muljono, Indonesia

09.20-09.30 Discussion

09.30-10.00

Coffee Break





Scientific Schedule



Friday

06.03.2020

Special Interest Group 2 - Nusa Dua Hall 1,2,3
Liver Fibrosis

- 10.00-11.30 **Chairman : Laurent Castera, France**
Co-Chair : IDN Wibawa, Indonesia
- 10.00-10.25 Algorithmic Approach for Diagnostic of F2 and F3 Fibrosis Using Non-Invasive Test
Laurent Castera, France
- 10.25-10.50 Innovation Imaging to Assess Liver Fibrosis: Focus on MR-Elastography
Sri Inggriani, Indonesia (Video conference)
- 10.50-11.15 Treatment in Liver Fibrosis : How Far We Have Achieved and Its Outcome
Kemal Fariz Kalista, Indonesia
- 11.15-11.30 Discussion

Symposium 9 - Nusa Dua Hall 4
New Issues on Hepatocellular Carcinoma

- 10.00-11.30 **Chairman : Han-Chieh Lin, Taiwan**
Co-Chair : Bogi Pratomo Wibowo, Indonesia
- 10.00-10.25 New Paradigm on Hepatocellular Carcinoma in NAFLD
Irsan Hasan, Indonesia
- 10.25-10.50 HCC Risk in HBV Patients with Metabolic Comorbidity
Han-Chieh Lin, Taiwan
- 10.50-11.15 Controversial Issue in Stopping Nucleos(t)ide Analogs in HbeAg Negative Patients
Jia-Horng Kao, Taiwan
- 11.15-11.30 Discussion

Symposium 10 - Session 1 - Presidential Plenary (Best Abstract) - Nusa Dua Hall 5

- 10.00-11.15 **Chairman : Rajender Reddy, USA**
Co-Chair : Guadalupe Garcia Tsao, USA
- 10.00-10.15 Liver Stiffness Measured by Fibroscan is Associated with Microvascular Complications in Filipinos with Diabetes Mellitus
Lella Sawadjaan
- 10.15-10.30 Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer - **Video Conference**
Stephanie Seah
- 10.30-10.45 MIP1?, sEselectin, Fractalkine and HLADR as early prognostic markers to discriminate Systemic Inflammatory Responses Syndrome (SIRS) from Acute on Chronic Liver Failure patients in 6 hours of admission: A single centre prospective study
Dr. Nirupma Trehanpati
- 10.45-11.00 Pegbelfermin (PGBF) reduces serum levels of secondary bile acids (BAs) in patients with non-alcoholic steatohepatitis (NASH) - **Video Conference**
Edgar D. Charles
- 11.00-11.15 The toll-like receptor 8 (TLR8) agonist selgantolimod induces a dose-dependent immune response in chronic hepatitis B patients - **Video Conference**
- 11.30-12.00

State of The Art Lecture 2 - Nusa Dua Hall 1,2,3
Chairman: Laurentius A. Lesmana, Indonesia
Co-Chair : Triyanta Yuli Pramana, Indonesia
Controversies and New Perspectives in Occult Hepatitis B Infection
Anna Lok, USA

12.00-13.30

Friday Prayer - Kintamani Hall 1 & Lunch - Singaraja Hall





Scientific Schedule



Friday

06.03.2020

Symposium 11 - Nusa Dua Hall 1,2,3 General Hepatology Update Symposium

- 13.30-15.00 **Chairman : Edward Gane, New Zealand**
Co-Chair : Igor Vladimirovich Malov, Russia
- 13.30-13.55 Acute Hepatitis A Infection: Outbreak and Impact on Vaccination
Irsan Hasan, Indonesia
- 13.55-14.20 Update on the Management of Hepatitis Delta Infection
Aghayeva Gulnara, Azerbaijan
- 14.20-14.45 Acute Hepatitis C infection: Management in the era of DAA
Chen-Hua Liu, Taiwan
- 14.45-15.00 Discussion

Symposium 12 - Nusa Dua Hall 4 Update on Biliary Diseases

- 13.30-15.00 **Chairman : Zaigham Abbas, Pakistan**
Co-Chair : Ruswhandi, Indonesia
- 13.30-13.50 The Challenging Diagnosis of Cholangiocarcinoma
Sahat B.R.E Matondang, Indonesia
- 13.50-14.10 Controversial Issue on Endoscopic Management in Malignant Biliary Obstruction
Kazuo Hara, Japan
- 14.10-14.30 Molecular Pathology of Biliary Tract Cancer
Ening Krisnuhoni, Indonesia
- 14.30-14.50 Surgical Management in Hepato-Cholangiocarcinoma
Wifanto S. Jeo, Indonesia
- 14.50-15.00 Discussion

APASL 2020 - Web Symposium (China Mainland) - Nusa Dua Hall 5

- 13.30-17.10 **Chairman : Lai Wei, China**
Co-Chair : JiDong Jia, China
- 13.30-13.35 Welcome Speech & Opening Remarks
Lai Wei, China
- 13.35-13.55 PBC:Management of UDCA Refractory PBS
JiDong Jia, China
- 13.55-14.15 Phase 4' real world' trials
Jinlin Hou, China
- 14.15-14.35 HBV reactivation and ACLF- new therapeutic targets
Fu-Sheng Wang, China
- 14.35-14.55 Prevention of HBV-related HCC
George K.K Lau, HongKong
- 14.55-15.15 NAFLD in Asian countries:From Risk factors,pathogenesis to clinical
Jian Gao Fan, China
- 15.15-15.35 Dynamics of immune dysregulation as a guide for prevention and intervention for sepsis
Qin Ning, China
- 15.35-15.55 Treatment in liver fibrosis: how far we have achieved and its outcome
Hong You, China
- 15.55-16.15 DAAs treatment in Chinese population:its impact after SVR
Guofeng Chen, China
- 16.15-16.35 Unmet needs in diagnosis and monitoring of portal hypertension
Xiaolong Qi, China
- 16.35-16.55 Asian WHA Representative
Dee Lee, China
- 16.55-17.05 Discussion
All Faculties
- 17.05-17.10 Closing
Ji Dong Jia, China

18.00-20.00

Faculty Dinner - Karang Asem 1 Ballroom, Grand Hyatt Hotel





Scientific Schedule



Saturday

07.03.2020

08.00-17.00

Re-registration & On site

Symposium 13 - Nusa Dua Hall 1,2,3
Presidential Plenary (Best Abstract)

08.00-09.30

Chairman : Ulrich H. Beuers, The Netherlands
Co-Chair : David H. Muljono, Indonesia

08.00-08.15

Efficacy and Safety of Oral TLR8 Agonist Selgantolimod (GS-9688) In Virally-Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2, Randomized, Double-Blind Placebo-Controlled, Multi-Center Study
Edward Gane, New Zealand

08.15-08.30

Hepatitis B virus (HBV) surface antigen (HBsAg) reduction with ISIS 505358 in treatment-naïve chronic hepatitis B (CHB) patients: a phase 2a, randomized, double-blind, placebo-controlled study

Dr. Dickens Theodore

08.30-08.45

CHI3L1 as a non-invasive marker for effective selecting of chronic HBV patient with normal ALT levels but with advanced liver fibrosis for treatment

Grace L.H Wong, HongKong

08.45-09.00

Preliminary results of Phase II study: 100% SVR rates following twelve-week treatment with narlaprevir ritonavir and sofosbuvir combination in patients with HCV Genotype 1 infection
Vasily A. Isakov

09.00-09.15

Transcriptional response to RO7020531, a novel double prodrug of a toll-like receptor 7 agonist, in whole blood of healthy subjects and chronic hepatitis B patients
Tomas Racek

Symposium 14- Nusa Dua Hall 4
Critical Care in Hepatology

08.00-09.30

Chairman : Saeed Hamid, Pakistan
Co-Chair : Putut Bayupurnama, Indonesia

08.00-08.20

Hepatitis Virus Infection and Its Impact on DILI
Chyntia O.M Jasirwan, Indonesia

08.20-08.40

Respiratory Failure in Liver Cirrhosis
Martin Rumende, Indonesia

08.40-09.00

Precaution and Assessment for DILI Prevention from Tuberculosis Drugs
Andri Sanityoso, Sulaiman, Indonesia

09.00-09.20

Fungal Infection Management in Liver Cirrhosis

09.20-09.30

Rino A. Gani, Indonesia
Discussion

Symposium 15- Nusa Dua Hall 5
Update on HCC

08.00-09.30

Chairman : TC Tseng, Taiwan
Co-Chair : Irsan Hasan, Indonesia

08.00-08.25

HBc Antigen and The Risk of HCC
TC Tseng, Taiwan

08.25-08.50

Variant HCCs, Diagnosis and Clinical Consequences

08.50-09.15

Ening Krisnuhoni, Indonesia
Stratification for Prediction in Patient's Outcome After Loco-Regional Therapy

09.15-09.30

TC Tseng, Taiwan
Discussion

09.30-10.00

Coffee Break





Scientific Schedule



Saturday

07.03.2020

Symposium 16 - Nusa Dua Hall 1,2,3
Liver Cirrhosis: New Issue on Management

10.00-11.30	Chairman : Rajender Reddy, USA Co-Chair : Fauzi Yusuf, Indonesia
10.00-10.25	Sarcopenia in Liver Cirrhosis : Update in Pathogenesis and Management Rajender Reddy, USA
10.25-10.50	MHE: Treat or Not Imelda M. Loho, Indonesia
10.50-11.15	Gut-Microbiota in Liver Cirrhosis: All or None Jasmohan Bajaj, USA
11.15-11.30	Discussion

Symposium 17 - Nusa Dua Hall 4
Women in Hepatology

10.00-11.30	Chairman : Rosmawati Mohammed, Malaysia Co-Chair : Fardah Akil, Indonesia
10.00-10.25	Woman and Alcoholic Liver Disease Fardah Akil, Indonesia
10.25-10.50	Fatty Liver in Pregnancy : Approach and Management Grace Wong, Hongkong
10.50-11.15	Management of Chronic Hepatitis B in Pregnancy Rosmawati Mohamed, Malaysia
11.15-11.30	Discussion

Symposium 18 - Nusa Dua Hall 5
Stem Cell in Liver Diseases

10.00-11.30	Chairman : Ian Homer Y. Cua, Philippines Co-Chair : Paulus Kusnanto, Indonesia
10.00-10.25	Hepatobiliary Stem Cells : Facts and Fancies Chyntia O.M Jasirwan, Indonesia
10.25-10.50	Current Perspective Regarding Stem Cells Based Therapy for non-viral Liver Disease Jeanne Adiwinata Pawitan, Indonesia
10.50-11.15	Safety Issue in Stem Cell Therapy Cosphiadi Irawaan, Indonesia
11.15-11.30	Discussion

Lunch - Singaraja Hall

Industrial Symposium 2 (by Mylan) - Nusa Dua Hall 1,2,3
Chronic Hepatitis B Management - Evolving Concepts and Practice Essentials

12.30-14.00	Chairman : Khin Maung Win, Myanmar Co-Chair : Rino A. Gani, Indonesia
12.30-12.50	Immunotolerant Phase in Chronic Hepatitis B: Should We Treat? C. Rinaldi A. Lesmana, Indonesia
12.50-13.10	Current Barriers to Hepatitis B Management-Asia Perspective Rosmawati Mohamed, Malaysia
13.10-13.30	Tenofovir Alafenamide in The Management of CHB: Time to Switch? Rino A. Gani, Indonesia
13.30-13.50	Asian Consensus Recommendations on Optimizing the Diagnosis and Initiation of Treatment of Hepatitis B Virus Infection in Resource-Limited Settings Edward Gane, Australia
13.50-14.00	Panel Discussion: Strategies to Increase Treatment Rate for Chronic Hepatitis B in South-East Asia





Scientific Schedule



Saturday

07.03.2020

Symposium 18 - Nusa Dua Hall 1,2,3
NAFLD and Other Related Problem

14.00-15.30	Chairman : Iswan A. Nusi, Indonesia Co-Chair : C. Rinaldi A. Lesmana, Indonesia	14.00-15.30
14.00-14.20	Update Pathophysiology Concept Related to Other Metabolic Parameters Hery Djagat Purnomo, Indonesia	14.00-14.25
14.20-14.40	The Role of Gut Dysbiosis and Its Impact on Management Jasmohan Bajaj, USA	14.25-14.50
14.40-15.00	NAFLD and Coronary Arterial Disease Chan Wah Keong, Malaysia	14.50-15.15
15.00-15.20	NAFLD and Non Alcoholic Fatty Pancreas Diseases : Together in Line? C. Rinaldi A. Lesmana, Indonesia	15.15-15.30
15.20-15.30	Discussion	

Symposium 19 - Nusa Dua Hall 4
Infection in Hepatobiliary Diseases

Chairman : Ian Homer Y. Cua, Phillipines Co-Chair : F. X. Pridady, Indonesia
Tropical infection and Liver Toxicity Saut Horas Nababan, Indonesia
Update Management in Pyogenic Liver Abscess Juferdy Kurniawan, Indonesia
Biliary Sepsis Management: Percutaneous, Endoscopic, or Surgical Necati Ormeci, Turkey
Discussion

APASL-EASL Joint Meeting - Uluwatu Hall 7
Managing Complication of Liver Disease

14.00-15.30	Chairman : Laurentius A. Lesmana, Indonesia Co-Chair : Ulrich H. Beuers, The Netherlands
14.00-14.25	Diagnosis of Cirrhosis and Portal Hypertension: Non Invasive or Invasive Test? Rino A. Gani, Indonesia
14.25-14.50	Bleeding and Thrombosis in End Stage Liver Disease Cosphiadi Irawan, Indonesia
14.50-15.15	Management of Cholestatic Diseases and It's Complications Ulrich H. Beuers, The Netherlands
15.15-15.30	Discussion
15.30-15.50	Coffee Break





Scientific Schedule



Saturday

07.03.2020

Symposium 20 - Nusa Dua Hall 1,2,3
Heart and Liver

15.50-17.20	Chairman : Gontar A. Siregar, Indonesia Co-Chair : Riki Tenggara, Indonesia
15.50-16.15	Cardiohepatic Disfunction: Interaction Pathogenesis and Clinical Manifestation Sally Aman Nasution, Indonesia
16.15-16.40	Myocardial dysfunction Associated with Hepatitis B Virus Infection Ian Homer Y. Cua, Philippines
16.40-17.05	Exercise for Liver Cirrhosis Patients Irsan Hasan, Indonesia
17.05-17.20	Discussion

Symposium 21- Nusa Dua Hall 4
Lung and Liver

15.50-17.20	Chairman : Aghayeva Gulnara, Azerbaijan- Co-Chair : Umimi Maimunah, Indonesia
15.50-16.10	Hepatopulmonary Syndrome: Update on Pathogenesis and Clinical Pictures Lianda Siregar, Indonesia
16.10-16.30	Update on Medical Treatment for the Hepatopulmonary Syndrome Ignatia Sinta Murti, Indonesia
16.30-16.50	The Impact of Liver Transplantation in the Patients with Hepatopulmonary Syndrome Vincent Ho, Australia
16.50-17.10	Personalizing Care in Patients with Liver Cirrhosis Aghayeva Gulnara, Azerbaijan
17.10-17.20	Discussion

Symposium 22 - Uluwatu Hall 7
Regression of Fibrosis and Portal Hypertension in CLD: Is It Really Feasible?

15.50-17.20	Chairman : Norifumi Kawada, Japan Co-Chair : Jordi Gracia-Sancho, Spain
15.50-16.10	Regression of Portal Hypertension - Mechanisms & New Therapeutics Jordi Gracia-Sancho, Spain
16.10-16.30	Regression of Fibrosis - Current Evidence & Future Perspectives Norifumi Kawada, Japan
16.30-16.50	Regression of Portal Hypertension & Fibrosis: Non-Viral Cirrhosis Saut Nababan, Indonesia
16.50-17.10	Non-Invasive Assessment of Portal Hypertension & Fibrosis Regression Kemal Fariz Kalista, Indonesia
17.10-17.20	Discussion

18.00-20.00 **GALA DINNER, AWARD PRESENTATION & CLOSING CEREMONY - Nusa Dua Hall 5**





Organized By :


PT. PROHEPA

Gedung Menara Salemba (3rd Floor)

Jalan Salemba Raya. No. 5, Jakarta Pusat 10440

Phone : +62 21-3970-0188

Email : prohepa.id@gmail.com



Website : www.apasl2020.org | Email : info@apasl2020.org



apasl2020_official



apasl2020



apasl2020 bali